Clinical Edge Journal Scan

CML-CP: NK cell subsets associated with relapse outcomes after TKI discontinuation


 

Key clinical point: Natural killer (NK) cell subsets, particularly CD56bright NK cells, were associated with relapse outcomes after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP). Moreover, interferon- a therapy gradually increased levels of CD56bright NK cells.

Major finding: Among patients who did not receive interferon- a therapy, the nonrelapsed vs relapsed patients had a significantly higher proportion of CD3-CD56+ NK cells ( P = .016), particularly CD3-CD56dimCD16+ NK cells ( P = .017), at 1 month after TKI discontinuation. Patients who received interferon- a therapy showed an increase in CD56bright NK cells at 3- and 6- months post-therapy vs pre-therapy ( P < .05).

Study details : Findings are from a retrospective analysis of 34 patients with CML-CP who discontinued TKI therapy after 3 or more years and at least 2 years of MR4.5. Twelve patients received interferon- a therapy post-TKI discontinuation.

Disclosures: This study was supported by the Capital Characteristic Clinic Project Foundation. The authors declared no conflict of interests.

Source: Kong J et al. Ann Hematol. 2021 Jul 19. doi: 10.1007/s00277-021-04606-9 .

Recommended Reading

Clinical Edge Journal Scan Commentary: CML August 2021
MDedge Hematology and Oncology
CML-CP: Risk for hepatotoxicity higher with new-generation TKIs vs imatinib
MDedge Hematology and Oncology
Higher risk of uncontrolled BP in patients with CML receiving nilotinib vs imatinib/dasatinib
MDedge Hematology and Oncology
Growth retardation with nilotinib treatment in pediatric patients with Ph+ CML
MDedge Hematology and Oncology
Superior COVID-19 outcomes in CML patients with controlled disease and on TKI therapies
MDedge Hematology and Oncology
CML-CP: Late responses may be possible in patients initially refractory to TKIs
MDedge Hematology and Oncology
CML-CP: Favorable outcomes post-TKI switch in patients intolerant/resistant to frontline 2G-TKI
MDedge Hematology and Oncology
Early response predictive of future stable MR4.5 in imatinib-treated patients with CML
MDedge Hematology and Oncology
Thyroid abnormalities associated with better treatment response in CML-CP patients on TKI therapy
MDedge Hematology and Oncology
Advanced phase CML: Factors influencing long-term survival after hematopoietic stem cell transplantation
MDedge Hematology and Oncology